Pluslife Biotech Founder, Prof. Songyang Contributes Viewpoints on Infectious Disease Prevention at the Symposium on Global Health

The 4th Symposium on Global Health was recently held in Beijing on September 14-15, 2023. The founder and head scientist of Pluslife Biotech, Prof. SONGYANG Zhou, gave a speech on the topic “New technologies for the surveillance and detection of infectious diseases” to deliver an outlook on strengthening global infectious disease diagnosis and surveillance with revolutionary molecular POCT technology.

The symposium, which is themed "Unite to combat infection, innovate for global health", is cosponsored by the Chinese Academy of Sciences and the University of Chinese Academy of Sciences, with support of the Bill & Melinda Gates Foundation. Leading experts in various medical fields and Chinese domestic technology departments were invited to the symposium to propose strategies for preventing the next pandemic and enhancing global health standards through cooperation and innovation.

In a world still grappling with the profound impact of the COVID-19 pandemic and the continuous threats posed by mass infectious diseases like monkeypox, influenza, and tuberculosis, Prof. SONGYANG remarked, “We found ourselves at the forefront of innovation and commitment to global pandemic prevention and empower primary healthcare worldwide with reliable and affordable molecular POCT solutions that make rapid and accurate diagnoses of infectious diseases possible.”

During the COVID-19 pandemic, thousands of Plusllife Mini Dock devices and millions of tests were used in German pharmacies, effectively halting transmission at community levels. Prof. SONGYANG discussed the situation in primary healthcare settings, emphasizing that “while PCR tests are costly and infeasible at clinics, molecular POCT represents an easily accessible and affordable solution for local communities, allowing them to achieve same-day test and treatment, and reduce the spread of hidden infections.” Since all raw materials, test cards, and devices are produced in-house using highly automated production lines, “Pluslife ensures a large-scale production capacity at lower costs compared to current mainstream molecular POCT products.”

At the same time, Pluslife is continuously broadening its pathogen test panel, with additional tests such as tuberculosis and malaria in the pipeline. Pluslife's objective is to develop cutting-edge technology and diagnostic tools empowering primary healthcare on a global scale and better molecular POCT solutions for the prevention of pandemics.